The spikes in my eyes
Release time:
2020-08-14
The peak
■ Jiang Xiaomeng
in my eyes will be the 11th anniversary of the peak start-up 60# and the 38 year of my work in the peak. From a young and ignorant teenager to now, my temples have begun to turn white. I have witnessed the nearly 2/3 course of the peak, including glory and depression, but more hope and longing.
Fortune magazine has reported that the average life expectancy of small and medium-sized enterprises in the United States is less than 7 years, while that of large enterprises is less than 40 years. The average life span of China's small and medium-sized enterprises is 2.5 years, and the average life span of group enterprises is 7 to 8 years. Among the many enterprises in our country, very few have the same peak life as us.
The peak with history
The development of the peak has experienced many great turning points worthy of memory and commemoration, such as setting up cement factory, cross-industry acquisition, merger, diversified operation, integration of pharmaceutical industry... Fortunately, I am a witness to these great events, even a witness.
When I entered the factory, in 1980 , Jinhua Cement Factory was still in the stage of coexistence of ordinary vertical kilns and mechanical vertical kilns. At that time, in the firing workshop, most of the feeding and unloading in the production process depended on manual work. When commuting in winter, you can often see the "brilliant" image of workers wearing hoods, working cotton-padded jackets, and rice basins under their armpits. Because the buttons of the cotton-padded jacket are easy to fall off, some employees still root straw ropes in their waists. The working conditions at that time could not be compared with those now. The dust was flying when adding and unloading materials. At the end of the day, everyone became the same appearance-because they were wearing masks, there were two black shadows on the bridge of the nose, and their bodies were covered in gray. Some people had too much dust on their faces and their eyebrows looked white.
Due to the lack of economy at that time, cement was regarded as a "tight commodity". The roads outside the factory area were full of cars buying cement, large trucks and small tractors, with long lines and even overnight queues. Sometimes it took two or three days for their turn. One winter when it snowed heavily and blocked the road, vehicles transporting limestone could not get in, and production was about to stop. At that time, I was still working in the raw material workshop. The factory organized employees to sweep snow and sweep all the way to the Kowloon mine along the Shuanglong Highway.
Although the working environment is so difficult, we have a sense of superiority regardless of cadres or employees, because we are workers!
With the progress of science and technology and the development of enterprises, 20th century 80# In the mid-1950s, Jianfeng established two branch factories and three branch factories successively through cooperation with township enterprises. Later, he established a building materials group and built the first batch of rotary kiln production lines in Zhejiang Province, which was later Jinma Factory. After entering 21nd century, we went out of the basin and built factories in Fuyang across regions. Until now, Jianfeng Cement has taken root in many provinces and cities across the country.
90 s of the last century, was the first step in the development of Jianfeng across industries. As the first general manager of a cable company, I started from scratch to supplement basic cable courses, engaged in construction, production, and market with my colleagues, and sold peak cables to most provinces and cities across the country. In 1996 , Jianfeng cross-regional merger of Linhai Pharmaceutical Factory, reorganization of the establishment of Zhejiang Jianfeng Haizhou Pharmaceutical Co., Ltd., to build a raw material drug production base. This requires considerable boldness when talents, technology and other factors were not available at that time. Although this first step was not satisfactory and later withdrew, this merger accumulated experience and trained a team for the development of Jianfeng in the pharmaceutical field. Only then did it acquire Jinhua Biochemical Pharmaceutical Factory, set up Jianfeng Pharmaceutical Company, and took a stake in Tianshili Group, finally forming a development pattern of cement and pharmaceutical dual main businesses.
tons to a cross-industry and cross-regional comprehensive enterprise group, and finally form a development strategy of "cooperative innovation to strengthen the main business; standardize science and seek development". It has created the current achievements of the peak.
3800 kilometers; "Jianfeng" brand cement is a famous brand product in Zhejiang, Hubei, Yunnan and other provinces and cities; all environmental protection indicators have reached or led the international and domestic standards, and the production process and technical indicators are among the best in the country. It is in cost control, quality control, The profit indicators of tons of cement are all ahead of the same industry, and this year has achieved the best results in history. The
76 document numbers, exceeding the sales of 10 .1 billion yuan. It has recruited talents from all walks of life in the country and trained a large number of teams who are loyal to the peak, love their posts and work hard, bear hardships and stand hard work, have combat effectiveness and professional qualities. In Tianjin, we have Tianjin Jianfeng Natural Products Company, a leading enterprise of plant extracts in China; in Jinhua, we have recently built a large-scale Jinxi pharmaceutical base and set up a Sino-German joint venture Jinder Baby Drug Company; this year, we have also participated in Beijing Huibaoyuan Biotechnology Company ...... While the pharmaceutical territory continues to expand, the health industry sector centered on Jianfeng Health Technology Company is also showing its embryonic form.
DPT under development is also the first major national innovation project in Jinhua's history. Many products have also been listed as the national high-tech industrialization demonstration project, the national key new product plan project and the national torch plan project. Cefmenoxime hydrochloride for injection has also created a history of over 100 million yuan in sales of single products; peak Pharmaceutical has also been rated as a national high-tech enterprise for more than 10 years.
Now, the peak is about to enter the 107 60
Finally, I would also like to thank the old peak people of all ages for their efforts in the cause of peak. We will not forget those old leaders, old employees, and old colleagues who have worked hard for the peak cause. Their conscientious and selfless dedication is the source and driving force of the development of the enterprise, and it also inspires generations of peak people to move forward courageously on the road of a century-old peak.
More information
Two Cement Enterprises Prosperous Production and Sales in May
With the gradual easing of the new crown epidemic, all over the project has started, Hubei, Yunnan two provinces cement market continued to improve, Daye peak cement company, Yunnan peak cement company two enterprises have recently shown a good momentum of production and sales. In May, the sales volume of Yunnan Jianfeng cement continued to rise. As of the time of publication, the average daily shipment volume reached more than 7400 tons, and the highest daily shipment volume reached more than 8700 tons, and the production capacity was fully released. Over the past few days, Yunnan Peak Packaging System has made great efforts to overcome the impact of narrow distribution sites and many cement varieties to ensure the completion of delivery tasks with good quality and quantity every day. In order to further balance production and sales and create conditions for the homogenization of cement delivered from the factory, Yunnan peak packaging system puts forward work requirements for relevant posts, emphasizes equipment inspection and process inspection during production, strictly implements safety operation procedures, and maintains safe and efficient operation of the system. Due to the impact of the new crown epidemic, Hubei cement market started late, Wuhan market is the hardest hit area, the current project construction is still not fully started, the volume pressure is greater. For this reason, daye peak departments cooperate closely, increase market development efforts, develop new mixing stations, focus on increasing the bulk share of Xianning, Huanggang and Wuhan markets, seize the opportunity of fine weather, and achieve the goal of rapid output. Internally, on the basis of equipment technical renovation and production capacity improvement, the delivery is effectively guaranteed, and the daily delivery capacity can basically be maintained at 10,000 tons. In May, Daye Peak sold more than 300000 tons of cement, an increase of 20% over the same period last year, with an average daily sales volume of more than 9900 tons, the highest in the current period since Daye Peak was put into production.
2020
07-31
The company's "safe production month" activities are about to start
June 2020 is the 19th national "safe production month", the theme of the activity is "eliminating hidden dangers of accidents and building a strong line of defense". A few days ago, the group company issued a notice to arrange the activities related to the organization of "safe production month" and put forward requirements. According to the group's "safe production month" activity plan, different key thematic activities will be held in the four weeks of June. The first week is the "Publicity and Safety Education Week", which focuses on the use of WeChat groups, electronic screens, publicity boards, banners, slogans and other forms for safety publicity, and organizes the study of national safety regulations, company safety system specifications and accident-free factory creation standards, Organize to watch safety warning education films, learn accident cases, etc., and improve employees' safety awareness by creating a safety atmosphere and organizing learning activities. The focus of the activities in the second week is "looking for potential sources of danger around you". Each unit takes departments and teams as units to investigate and analyze the potential risk factors in the process of daily production, maintenance and operation, find out the hazard sources that have not been included in the scope of risk point control, and report to the safety management department of the unit to form a risk assessment report, put forward solutions or suggestions, and supervise the implementation of rectification and timely eliminate potential safety hazards. The third week is the "on-site safety innovation achievements exhibition week", which focuses on the achievements of each unit in on-site safety management and on-site safety facilities in the past year, which are displayed in the form of pictures and texts through beautiful articles and wechat, so as to learn from each other and promote common progress. The fourth week is the "safety training and drill week", and the group company organizes the standardization of safety production and the elimination of hidden dangers.
2020
07-31
Jianfeng Pharmaceuticals ranks among the top 50 creative enterprises in Jinhua
News from our newspaper April 26 is World Intellectual Property Day. Jinhua City released the list of "Top 50 Creative Enterprises" for the first time. Jianfeng Pharmaceutical Company entered the list and ranked second among the enterprises in Jinhua Development Zone. The selection of creative enterprises, the enterprise holds the effective invention patent as the main indicator. Over the years, Jianfeng Pharmaceutical Co., Ltd. has taken "intellectual property rights help enterprise development, and scientific and technological innovation creates a century-old peak" as the company's intellectual property policy. It has actively cooperated with China Pharmaceutical University, Sichuan Institute of Antibiotic Industry, Zhejiang University of Technology, Xiamen University and other units to build a scientific research and innovation platform integrating production, learning and research, and flexibly introduced Academician Wang Guangji and Academician Shan Weiguang with the chief scientist system, according to the direction of enterprise development strategy to carry out scientific research work, and achieved fruitful results. In 2019, Spike Pharmaceuticals applied for 2 invention patents and obtained 5 patent authorizations, including 1 invention. By the end of 2019, Spike Pharmaceuticals had obtained a total of 37 patents (including 2 PCT patents), of which 28 were inventions. In recent years, in order to better integrate with the international market, Jianfeng Pharmaceutical has made a complete patent layout for the new drug DPT under development, and has applied for patent protection in multiple countries through the PCT application channel for core patents, and finally in the high-level United States. And Japan was authorized to lay a solid foundation for the product to enter these two overseas high-end markets. At the same time, around the core patent, applied for the preparation, crystal type patent and obtained the invention patent authorization 5. In addition, pharmaceutical companies have also developed patents for other varieties under research.
2020
07-31
Jianfeng Pharmaceuticals ranks among the top 50 creative enterprises in Jinhua
News from our newspaper April 26 is World Intellectual Property Day. Jinhua City released the list of "Top 50 Creative Enterprises" for the first time. Jianfeng Pharmaceutical Company entered the list and ranked second among the enterprises in Jinhua Development Zone. The selection of creative enterprises, the enterprise holds the effective invention patent as the main indicator. Over the years, Jianfeng Pharmaceutical Co., Ltd. has taken "intellectual property rights help enterprise development, and scientific and technological innovation creates a century-old peak" as the company's intellectual property policy. It has actively cooperated with China Pharmaceutical University, Sichuan Institute of Antibiotic Industry, Zhejiang University of Technology, Xiamen University and other units to build a scientific research and innovation platform integrating production, learning and research, and flexibly introduced Academician Wang Guangji and Academician Shan Weiguang with the chief scientist system, according to the direction of enterprise development strategy to carry out scientific research work, and achieved fruitful results. In 2019, Spike Pharmaceuticals applied for 2 invention patents and obtained 5 patent authorizations, including 1 invention. By the end of 2019, Spike Pharmaceuticals had obtained a total of 37 patents (including 2 PCT patents), of which 28 were inventions. In recent years, in order to better integrate with the international market, Jianfeng Pharmaceutical has made a complete patent layout for the new drug DPT under development, and has applied for patent protection in multiple countries through the PCT application channel for core patents, and finally in the high-level United States. And Japan was authorized to lay a solid foundation for the product to enter these two overseas high-end markets. At the same time, around the core patent, applied for the preparation, crystal type patent and obtained the invention patent authorization 5. In addition, pharmaceutical companies have also developed patents for other varieties under research.
2020
07-30
Jianfeng Pharmaceuticals ranks among the top 50 creative enterprises in Jinhua
News from our newspaper April 26 is World Intellectual Property Day. Jinhua City released the list of "Top 50 Creative Enterprises" for the first time. Jianfeng Pharmaceutical Company entered the list and ranked second among the enterprises in Jinhua Development Zone. The selection of creative enterprises, the enterprise holds the effective invention patent as the main indicator. Over the years, Jianfeng Pharmaceutical Co., Ltd. has taken "intellectual property rights help enterprise development, and scientific and technological innovation creates a century-old peak" as the company's intellectual property policy. It has actively cooperated with China Pharmaceutical University, Sichuan Institute of Antibiotic Industry, Zhejiang University of Technology, Xiamen University and other units to build a scientific research and innovation platform integrating production, learning and research, and flexibly introduced Academician Wang Guangji and Academician Shan Weiguang with the chief scientist system, according to the direction of enterprise development strategy to carry out scientific research work, and achieved fruitful results. In 2019, Spike Pharmaceuticals applied for 2 invention patents and obtained 5 patent authorizations, including 1 invention. By the end of 2019, Spike Pharmaceuticals had obtained a total of 37 patents (including 2 PCT patents), of which 28 were inventions. In recent years, in order to better integrate with the international market, Jianfeng Pharmaceutical has made a complete patent layout for the new drug DPT under development, and has applied for patent protection in multiple countries through the PCT application channel for core patents, and finally in the high-level United States. And Japan was authorized to lay a solid foundation for the product to enter these two overseas high-end markets. At the same time, around the core patent, applied for the preparation, crystal type patent and obtained the invention patent authorization 5. In addition, pharmaceutical companies have also developed patents for other varieties under research.
2020
07-22
On April 24, Jiang Xiaomeng, chairman of the group company, presided over the 14th meeting of the 10th board of directors of the company, and deliberated and passed 14 related reports and motions such as the 2019 annual board of directors report, the 2019 general manager business report and the 2019 annual report. The general manager's report pointed out that 2019 is the first year of the implementation of the group's new five-year strategic development plan (2019-2023) and the new three-year business plan (2019-2021) for each business sector. the management team has carried out various operation and management work in an orderly manner around the general policy of "innovation and reform, integration and promotion, scientific layout and steady development", and has better completed the business objectives set by the board of directors at the beginning of the year. In the whole year, the company achieved a total operating income of 3.548 billion billion yuan, an increase of 5.51 percent over the same period last year; net profit attributable to shareholders was 0.725 billion billion yuan, with earnings per share reaching 2.11 billion yuan, an increase of 23.14 percent over the same period last year, a record high; total assets at the end of the year were 5.475 billion billion yuan, an increase of 11.71 percent over the same period last year; and net assets attributable to shareholders were 3.789 billion billion yuan, an increase of 19.81 percent. During the reporting period, the company's two main businesses have achieved great development, benefiting from the further promotion of supply-side structural reform, the overall operation of the cement industry in 2019 is stable, and the industry benefits are further improved. During the reporting period, the company made new progress in the construction of cement projects, completed the acquisition, capital increase and name change of Guizhou Mingchuan (Guizhou Huangping Jianfeng Cement Co., Ltd.), and continued to invest in the construction of its new dry cement production line with a daily output of 4500 tons of clinker.
2020
07-31